Please ensure Javascript is enabled for purposes of website accessibility

Vaxart Ramps Up Coronavirus Vaccine Production

By Joe Tenebruso – Oct 7, 2020 at 4:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is expanding its manufacturing network ahead of its clinical trials.

Vaxart (VXRT 1.22%) is gearing up for a potential roll-out of its experimental COVID-19 vaccine. 

The clinical-stage biotechnology company is expanding its partnership with Kindred Biosciences (KIN) to manufacture its oral vaccine candidate for the novel coronavirus. Under the terms of the deal, Kindred's plants will produce bioreactors for Vaxart's clinical trials.

Bioreactors in a laboratory.

Vaxart and Kindred Biosciences are teaming up to advance their COVID-19 vaccine production capabilities. Image source: Getty Images.

"We are very pleased to have secured commercial-scale bulk manufacturing with KindredBio, which has state-of-the-art capabilities in viral vector manufacturing," Vaxart CEO Andrei Floroiu said in a press release. "This is an essential next step in advancing our oral tablet vaccine candidate for COVID-19, which we believe could accelerate mass vaccination campaigns globally."

Vaxart's vaccine is administered by tablet rather than the more common method of injection. That could make it easier to store and ship. An oral vaccine might also provide a more pleasant patient experience.

Investors are excited about the vaccine's potential. Vaxart's shares are up a staggering 1,890% so far in 2020. 

Still, it should be noted that Vaxart's phase 1 study began in September, and its clinical trial remains in its early stages. Vaxart's vaccine has not yet been proven to be both safe and effective, and it faces formidable competition from more than 100 other vaccine makers. 

Thus, Vaxart's stock remains a high-risk investment, albeit one with tremendous upside potential if its vaccine development efforts are successful.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Kindred Biosciences Stock Quote
Kindred Biosciences
Vaxart, Inc Stock Quote
Vaxart, Inc
$1.25 (1.22%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.